IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company, announced that the Investigational New Drug (IND) application for its in-house developed BCMA CAR-T CT103A (equecabtagene autoleucel) has been approved by the US Food and Drug Administration (FDA) for use in US clinical trials for relapsed/refractory multiple myeloma (R/R MM).
Multiple myeloma is a deadly blood cancer that often infiltrates the bone marrow causing anaemia, kidney failure, immune problems, and bone fractures. For multiple myeloma patients, common first-line drug treatments include proteasome inhibitors, immunomodulatory drugs, and alkylating agents. While treatment may result in remission, most patients will inevitably enter the relapsed or refractory stage as there
